Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 40c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.74), $0.40 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $166.8 million versus the consensus estimate of $197.77 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• UBS Downgrades Core Natural Resources (CNR) to Neutral
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance